Shire-话题@MedSci

#Shire#

18篇内容 | 627人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1675169, encodeId=695216e5169f9, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=美国FDA专家组一致同意Shire的普卢卡必利治疗慢性特发性便秘, objectType=article, longId=151514, objectId=abb1151514a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abb1151514a2, replyNumber=0, likeNumber=29, createdTime=2019-01-21, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abb1151514a2, moduleTitle=美国FDA专家组一致同意Shire的普卢卡必利治疗慢性特发性便秘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abb1151514a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675167, encodeId=46df16e5167f8, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=Shire公司Vonvendi美国获批用于血管性血友病患者的围术期处理, objectType=article, longId=135844, objectId=96b4135844e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96b4135844e7, replyNumber=0, likeNumber=30, createdTime=2018-05-21, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96b4135844e7, moduleTitle=Shire公司Vonvendi美国获批用于血管性血友病患者的围术期处理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96b4135844e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675168, encodeId=0ed416e516819, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=法国第二大制药公司施维雅（Servier）24亿美元收购Shire公司的肿瘤业务经营权, objectType=article, longId=147989, objectId=442014e9890d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=442014e9890d, replyNumber=0, likeNumber=28, createdTime=2019-04-30, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=442014e9890d, moduleTitle=法国第二大制药公司施维雅（Servier）24亿美元收购Shire公司的肿瘤业务经营权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=442014e9890d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675170, encodeId=ec5816e5170b3, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=CHMP支持Shire旗下Takhzyro用于预防遗传性血管性水肿的发作, objectType=article, longId=151515, objectId=6107151515af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6107151515af, replyNumber=0, likeNumber=31, createdTime=2019-07-25, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6107151515af, moduleTitle=CHMP支持Shire旗下Takhzyro用于预防遗传性血管性水肿的发作, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6107151515af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675166, encodeId=fc9a16e516655, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=Shire的lanadelumab获欧盟快速审查, objectType=article, longId=131135, objectId=30ef1311358f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30ef1311358f, replyNumber=0, likeNumber=35, createdTime=2018-10-23, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30ef1311358f, moduleTitle=Shire的lanadelumab获欧盟快速审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30ef1311358f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675165, encodeId=faf116e516508, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=对Shire的HAE药物进行优先审查, objectType=article, longId=130444, objectId=065413044401, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=065413044401, replyNumber=0, likeNumber=37, createdTime=2018-10-03, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=065413044401, moduleTitle=对Shire的HAE药物进行优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=065413044401)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675164, encodeId=1f1416e5164b3, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=Shire制药的长效血友病疗法获欧盟首肯, objectType=article, longId=127146, objectId=e72512e14614, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e72512e14614, replyNumber=0, likeNumber=30, createdTime=2018-07-07, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e72512e14614, moduleTitle=Shire制药的长效血友病疗法获欧盟首肯, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e72512e14614)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675162, encodeId=ca9116e51626d, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=FDA批准Shire血友病药物新增加适应症, objectType=article, longId=86134, objectId=f8d8861340e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8d8861340e, replyNumber=0, likeNumber=25, createdTime=2017-10-26, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8d8861340e, moduleTitle=FDA批准Shire血友病药物新增加适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8d8861340e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675161, encodeId=55d116e516156, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=Shire胰腺癌新药Onivyde获欧盟委员会批准, objectType=article, longId=80912, objectId=7f368091298, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f368091298, replyNumber=0, likeNumber=40, createdTime=2017-03-29, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f368091298, moduleTitle=Shire胰腺癌新药Onivyde获欧盟委员会批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f368091298)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675158, encodeId=257516e51583e, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=英国Brompton皇家医院Nick Cheshire教授参观访问曲乐丰血管外科团队并作学术交流, objectType=article, longId=71478, objectId=0a9ee147863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a9ee147863, replyNumber=0, likeNumber=28, createdTime=2017-05-30, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a9ee147863, moduleTitle=英国Brompton皇家医院Nick Cheshire教授参观访问曲乐丰血管外科团队并作学术交流, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a9ee147863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675163, encodeId=db4516e5163af, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=Shire胰腺癌药物Onivyde惨遭英国NICE拒绝！, objectType=article, longId=94073, objectId=0c71940e386, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c71940e386, replyNumber=0, likeNumber=37, createdTime=2017-07-03, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c71940e386, moduleTitle=Shire胰腺癌药物Onivyde惨遭英国NICE拒绝！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c71940e386)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675160, encodeId=6eb216e516042, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=Shire在美国推出干眼病新药Xiidra，艾尔健丽眼达（Restasis）霸主地位不保, objectType=article, longId=76571, objectId=d532e6571f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d532e6571f1, replyNumber=0, likeNumber=40, createdTime=2017-04-07, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d532e6571f1, moduleTitle=Shire在美国推出干眼病新药Xiidra，艾尔健丽眼达（Restasis）霸主地位不保, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d532e6571f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675159, encodeId=427d16e5159c8, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=Shire将再次提交小儿多动症药物SHP 465美国上市申请, objectType=article, longId=72520, objectId=6d2fe2520b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d2fe2520b6, replyNumber=0, likeNumber=32, createdTime=2017-04-21, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d2fe2520b6, moduleTitle=Shire将再次提交小儿多动症药物SHP 465美国上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d2fe2520b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675157, encodeId=b97d16e5157b7, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=FDA批准NPS罕见病药物Natpara，Shire收购初现收获, objectType=article, longId=46331, objectId=3dfa4633146, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dfa4633146, replyNumber=0, likeNumber=40, createdTime=2015-02-23, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dfa4633146, moduleTitle=FDA批准NPS罕见病药物Natpara，Shire收购初现收获, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dfa4633146)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675156, encodeId=b08816e515644, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=巴马猛于虎|艾伯维重新考虑并购，Shire市值消失$135亿, objectType=article, longId=41332, objectId=76e7413322a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76e7413322a, replyNumber=0, likeNumber=38, createdTime=2014-11-03, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76e7413322a, moduleTitle=巴马猛于虎|艾伯维重新考虑并购，Shire市值消失$135亿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76e7413322a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675154, encodeId=741216e515438, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=艾伯维550亿美元收购Shire, objectType=article, longId=38058, objectId=9fcb38058f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fcb38058f2, replyNumber=0, likeNumber=33, createdTime=2014-09-12, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fcb38058f2, moduleTitle=艾伯维550亿美元收购Shire, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fcb38058f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675155, encodeId=d93816e515578, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=伯维550亿美元收购Shire交易泡汤？？, objectType=article, longId=40849, objectId=74554084960, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74554084960, replyNumber=0, likeNumber=23, createdTime=2015-05-17, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74554084960, moduleTitle=伯维550亿美元收购Shire交易泡汤？？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74554084960)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1675153, encodeId=55cc16e515375, content=<a href='/topic/show?id=cb2116259ca' target=_blank style='color:#2F92EE;'>#Shire#</a>, objectTitle=Am J Gastroenterol：结肠镜更佳检查时长9分钟（Hampshire结肠镜登记研究）, objectType=article, longId=30223, objectId=c2033022333, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2033022333, replyNumber=0, likeNumber=25, createdTime=2014-07-20, rootId=0, userName=liuli5088, userId=cdbc27169769, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2033022333, moduleTitle=Am J Gastroenterol：结肠镜更佳检查时长9分钟（Hampshire结肠镜登记研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2033022333)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Shire

2020-05-29

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

美国FDA专家组一致同意Shire的普卢卡必利治疗慢性特发性便秘

2019-01-21

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

Shire公司Vonvendi美国获批用于血管性血友病患者的围术期处理

2018-05-21

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

法国第二大制药公司施维雅（Servier）24亿美元收购Shire公司的肿瘤业务经营权

2019-04-30

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

CHMP支持Shire旗下Takhzyro用于预防遗传性血管性水肿的发作

2019-07-25

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

Shire的lanadelumab获欧盟快速审查

2018-10-23

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

对Shire的HAE药物进行优先审查

2018-10-03

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

Shire制药的长效血友病疗法获欧盟首肯

2018-07-07

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

FDA批准Shire血友病药物新增加适应症

2017-10-26

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

Shire胰腺癌新药Onivyde获欧盟委员会批准

2017-03-29

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

英国Brompton皇家医院Nick Cheshire教授参观访问曲乐丰血管外科团队并作学术交流

2017-05-30

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

Shire胰腺癌药物Onivyde惨遭英国NICE拒绝！

2017-07-03

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

Shire在美国推出干眼病新药Xiidra，艾尔健丽眼达（Restasis）霸主地位不保

2017-04-07

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

Shire将再次提交小儿多动症药物SHP 465美国上市申请

2017-04-21

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

FDA批准NPS罕见病药物Natpara，Shire收购初现收获

2015-02-23

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

巴马猛于虎|艾伯维重新考虑并购，Shire市值消失$135亿

2014-11-03

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

艾伯维550亿美元收购Shire

2014-09-12

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

伯维550亿美元收购Shire交易泡汤？？

2015-05-17

liuli5088 (审核中...)

前往app查看评论内容

#Shire#

Am J Gastroenterol：结肠镜更佳检查时长9分钟（Hampshire结肠镜登记研究）

2014-07-20

科室
- - 订阅+
  - 更多科室
工具
服务